Using light to change glioma stem cells for better treatment outcomes
Official title: Patterned optogenetic neuromodulation to reprogram glioma stem cells
Funded at Methodist Hospital Research Institute · NIH-10816836 · Data updated 2026-11-12
This study is exploring a new way to treat glioblastoma by using light to change the behavior of stubborn cancer cells, with the hope of making them easier to treat and improving outcomes for patients battling this tough brain cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | January 9, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $444,125 |
| NIH project number | 1R21NS127229-01A1 |
| Project ID | NIH-10816836 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who have not responded adequately to standard treatments.
✕Less likely to help
Patients with glioblastoma who are in advanced stages of the disease or have already undergone extensive treatment may not benefit from this research.
What this research studies
This research investigates a novel approach to treating glioblastoma, a highly aggressive brain cancer, by targeting glioma stem-like cells (GSCs) that contribute to the cancer's resistance to standard therapies. The study employs patterned optogenetic neuromodulation to manipulate the electrical signals within these cells, aiming to reprogram them into a less malignant state that is more responsive to treatment. By altering the membrane potential of GSCs, the researchers hope to enhance the effectiveness of existing therapies like chemotherapy and radiation. This innovative method could lead to improved outcomes for patients suffering from this challenging condition.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially extending survival and improving quality of life for patients.
How similar studies have gone: While the use of optogenetics in cancer treatment is a relatively novel approach, preliminary studies have shown promise in reprogramming cancer cells, suggesting potential for success in this area.
Where this research is happening
-
Methodist Hospital Research Institute
Houston, United States Active
Researchers
- Principal investigator: Rostomily, Robert C — Methodist Hospital Research Institute
- Study coordinator: Rostomily, Robert C
Related research
Other NIH-funded projects on the same topics.
-
Next‑gen oncolytic virus therapy for glioblastoma targeting AKT and ERK
A new cancer therapy using an engineered oncolytic virus to fight glioblastoma by blocking AKT/ERK signals and boosting the body’s immune response, with potential to reduce seizures and improve quality of life.
-
Bone marrow immune cells and glioma progression in teens and young adults
A study in adolescents and young adults with brain tumors looks at how immune cells from bone marrow may influence the progression from low-grade to high-grade gliomas.
-
How RNA Splicing Might Shape Glioma Cell States and Therapy Response
A small NIH-funded project will study how alternative RNA splicing influences glioma cell identities and treatment resistance in patient-derived cells.
-
Liquid biopsy for monitoring high-grade glioma using patient-specific DNA junctions
A Mayo Clinic team tests a blood test that looks for unique tumor DNA pieces in glioblastoma patients to monitor disease without frequent scans.
-
Deciphering how a brain cell pH helper influences glioma growth
A study is exploring whether a brain cell pH regulator (Slc4a4) affects the growth and blood vessel changes of malignant glioma to identify new angles for treatment.
-
Predicting how gene therapy spreads in glioblastoma after surgery to improve treatment coverage
This project uses a gene therapy that helps radiation work better against glioblastoma and builds computer models to predict where the therapy reaches after surgical tumor removal.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.